<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36268783</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1470-8736</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><Issue>20</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Clinical science (London, England : 1979)</Title><ISOAbbreviation>Clin Sci (Lond)</ISOAbbreviation></Journal><ArticleTitle>Therapeutic use of calpeptin in COVID-19 infection.</ArticleTitle><Pagination><StartPage>1439</StartPage><EndPage>1447</EndPage><MedlinePgn>1439-1447</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1042/CS20220638</ELocationID><Abstract><AbstractText>This perspective considers the benefits of the potential future use of the cell permeant calpain inhibitor, calpeptin, as a drug to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recent work has reported calpeptin's capacity to inhibit entry of the virus into cells. Elsewhere, several drugs, including calpeptin, were found to be able to inhibit extracellular vesicle (EV) biogenesis. Unsurprisingly, because of similarities between viral and EV release mechanisms, calpeptin has also been shown to inhibit viral egress. This approach, identifying calpeptin, through large-scale screening studies as a candidate drug to treat COVID-19, however, has not considered the longer term likely benefits of calpain inhibition, post-COVID-19. This perspective will reflect on the capacity of calpeptin for treating long COVID by inhibiting the overproduction of neutrophil extracellular traps potentially damaging lung cells and promoting clotting, together with limiting associated chronic inflammation, tissue damage and pulmonary fibrosis. It will also reflect on the tolerated and detrimental in vivo side-effects of calpain inhibition from various preclinical studies.</AbstractText><CopyrightInformation>&#xa9; 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inal</LastName><ForeName>Jameel</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7200-0363</Identifier><AffiliationInfo><Affiliation>School of Human Sciences, London Metropolitan University, U.K.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biosciences Research Group, School of Life and Medical Sciences, University of Hertfordshire, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paizuldaeva</LastName><ForeName>Ainura</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Human Sciences, London Metropolitan University, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terziu</LastName><ForeName>Esmeralda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Human Sciences, London Metropolitan University, U.K.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Sci (Lond)</MedlineTA><NlmUniqueID>7905731</NlmUniqueID><ISSNLinking>0143-5221</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>18X9FR245W</RegistryNumber><NameOfSubstance UI="C071482">calpeptin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Extracellular Vesicles</Keyword><Keyword MajorTopicYN="N">calpeptin</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare that there are no competing interests associated with the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>21</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36268783</ArticleId><ArticleId IdType="pmc">PMC9594985</ArticleId><ArticleId IdType="doi">10.1042/CS20220638</ArticleId><ArticleId IdType="pii">231959</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Das A., Roy S., Swarnakar S. and Chatterjee N. (2021) Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. Clin. Immunol. 231, 108804 10.1016/j.clim.2021.108804</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108804</ArticleId><ArticleId IdType="pmc">PMC8378842</ArticleId><ArticleId IdType="pubmed">34303849</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavillegrand J.R., Garnier M., Spaeth A., Mario N., Hariri G., Pilon A.et al. . (2021) Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann. Intensive Care 11, 9 10.1186/s13613-020-00798-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00798-x</ArticleId><ArticleId IdType="pmc">PMC7804215</ArticleId><ArticleId IdType="pubmed">33439360</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustine J.N. and Jones D. (2021) Immunopathology of hyperinflammation in COVID-19. Am. J. Pathol. 191, 4&#x2013;17 10.1016/j.ajpath.2020.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.08.009</ArticleId><ArticleId IdType="pmc">PMC7484812</ArticleId><ArticleId IdType="pubmed">32919977</ArticleId></ArticleIdList></Reference><Reference><Citation>Hikmet F., M&#xe9;ar L., Edvinsson &#xc5;., Micke P., Uhl&#xe9;n M. and Lindskog C. (2020) The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16, e9610 10.15252/msb.20209610</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20209610</ArticleId><ArticleId IdType="pmc">PMC7383091</ArticleId><ArticleId IdType="pubmed">32715618</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon K.H., Leist S.R., Okuda K., Dang H., Fritch E.J., Gully K.L.et al. ., SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Sci. Transl. Med. 0, eabo5070 10.1126/scitranslmed.abo5070</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5070</ArticleId><ArticleId IdType="pmc">PMC9273046</ArticleId><ArticleId IdType="pubmed">35857635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara F., Granata G., Pelliccia C., La Porta R. and Vitiello A. (2020) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur. J. Clin. Pharmacol. 76, 1615&#x2013;1618 10.1007/s00228-020-02947-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-020-02947-4</ArticleId><ArticleId IdType="pmc">PMC7320911</ArticleId><ArticleId IdType="pubmed">32594204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahilog Z., Zhao H., Wu L., Alam A., Eguchi S., Weng H.et al. . (2020) The role of neutrophil NETosis in organ injury: novel inflammatory cell death mechanisms. Inflammation 43, 2021&#x2013;2032 10.1007/s10753-020-01294-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-020-01294-x</ArticleId><ArticleId IdType="pmc">PMC7443373</ArticleId><ArticleId IdType="pubmed">32830308</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzas E.I., Gy&#xf6;rgy B., Nagy G., Falus A. and Gay S. (2014) Emerging role of extracellular vesicles in inflammatory diseases. Nat. Rev. Rheumatol. 10, 356&#x2013;364 10.1038/nrrheum.2014.19</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2014.19</ArticleId><ArticleId IdType="pubmed">24535546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanyu Z. and Feilong H. (2019) Emerging role of extracellular vesicles in lung injury and inflammation. Biomed. Pharmacother. 113, 108748 10.1016/j.biopha.2019.108748</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.108748</ArticleId><ArticleId IdType="pubmed">30877881</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L. and Bates P. (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. PNAS 102, 11876&#x2013;11881 10.1073/pnas.0505577102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0505577102</ArticleId><ArticleId IdType="pmc">PMC1188015</ArticleId><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M.M., Yang W.L., Yang F.Y., Zhang L., Huang W.J., Hou W.et al. . (2021) Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct. Targeted Ther. 6, 134 10.1038/s41392-021-00558-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00558-8</ArticleId><ArticleId IdType="pmc">PMC7997800</ArticleId><ArticleId IdType="pubmed">33774649</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Luo S., Libby P. and Shi G.P. (2020) Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients. Pharmacol. Therapeut. 213, 107587 10.1016/j.pharmthera.2020.107587</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107587</ArticleId><ArticleId IdType="pmc">PMC7255230</ArticleId><ArticleId IdType="pubmed">32470470</ArticleId></ArticleIdList></Reference><Reference><Citation>Mediouni S., Mou H., Otsuka Y., Jablonski J.A., Adcock R.S., Batra L.et al. . (2022) Identification of potent small molecule inhibitors of SARS-CoV-2 entry. SLAS Discov. 27, 8&#x2013;19 10.1016/j.slasd.2021.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.slasd.2021.10.012</ArticleId><ArticleId IdType="pmc">PMC8577999</ArticleId><ArticleId IdType="pubmed">35058179</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;nther S., Reinke P.Y.A., Fern&#xe1;ndez-Garc&#xed;a Y., Lieske J., Lane T.J., Ginn H.M.et al. . (2021) X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science (New York, N.Y.) 372, 642&#x2013;646 10.1126/science.abf7945</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf7945</ArticleId><ArticleId IdType="pmc">PMC8224385</ArticleId><ArticleId IdType="pubmed">33811162</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Pradhan M., Gorshkov K., Petersen J.D., Shen M., Guo H.et al. . (2022) A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. SLAS Discov. 27, 86&#x2013;94 10.1016/j.slasd.2021.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.slasd.2021.12.005</ArticleId><ArticleId IdType="pmc">PMC8720380</ArticleId><ArticleId IdType="pubmed">35086793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.Z., Xu M., Pradhan M., Gorshkov K., Petersen J.D., Straus M.R.et al. . (2020) Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles. ACS Pharmacol. Transl. Sci. 3, 1165&#x2013;1175 10.1021/acsptsci.0c00112</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.0c00112</ArticleId><ArticleId IdType="pmc">PMC7586456</ArticleId><ArticleId IdType="pubmed">33330839</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva L., Yuan S., Yin X., Martin-Sancho L., Matsunaga N., Pache L.et al. . (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113&#x2013;119 10.1038/s41586-020-2577-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2577-1</ArticleId><ArticleId IdType="pmc">PMC7603405</ArticleId><ArticleId IdType="pubmed">32707573</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco M.D., Ma C., Lagarias P., Gao A., Townsend J.A., Meng X.et al. . (2020) Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. Sci. Adv. 6, eabe0751 10.1126/sciadv.abe0751</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe0751</ArticleId><ArticleId IdType="pmc">PMC7725459</ArticleId><ArticleId IdType="pubmed">33158912</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Sacco M.D., Hurst B., Townsend J.A., Hu Y., Szeto T.et al. . (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30, 678&#x2013;692 10.1038/s41422-020-0356-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0356-z</ArticleId><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Ma C., Szeto T., Hurst B., Tarbet B. and Wang J. (2021) Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses. ACS Infect. Dis. 7, 586&#x2013;597 10.1021/acsinfecdis.0c00761</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00761</ArticleId><ArticleId IdType="pmc">PMC7944397</ArticleId><ArticleId IdType="pubmed">33645977</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;ry C., Witwer K.W., Aikawa E., Alcaraz M.J., Anderson J.D., Andriantsitohaina R.et al. . (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 10.1080/20013078.2018.1535750</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20013078.2018.1535750</ArticleId><ArticleId IdType="pmc">PMC6322352</ArticleId><ArticleId IdType="pubmed">30637094</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sousa K.P., Rossi I., Abdullahi M., Ramirez M.I., Stratton D. and Inal J.M. (2022) Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. e1835 10.1002/wnan.1835</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wnan.1835</ArticleId><ArticleId IdType="pmc">PMC10078256</ArticleId><ArticleId IdType="pubmed">35898167</ArticleId></ArticleIdList></Reference><Reference><Citation>Inal J.M., Ansa-Addo E.A. and Lange S. (2013) Interplay of host-pathogen microvesicles and their role in infectious disease. Biochem. Soc. Trans. 41, 258&#x2013;262 10.1042/BST20120257</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120257</ArticleId><ArticleId IdType="pubmed">23356293</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolte-'t Hoen E., Cremer T., Gallo R.C. and Margolis L.B. (2016) Extracellular vesicles and viruses: are they close relatives? PNAS 113, 9155&#x2013;9161 10.1073/pnas.1605146113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605146113</ArticleId><ArticleId IdType="pmc">PMC4995926</ArticleId><ArticleId IdType="pubmed">27432966</ArticleId></ArticleIdList></Reference><Reference><Citation>Inal J.M. and Jorfi S. (2013) Coxsackievirus B transmission and possible new roles for extracellular vesicles. Biochem. Soc. Trans. 41, 299&#x2013;302 10.1042/BST20120272</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120272</ArticleId><ArticleId IdType="pubmed">23356301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S., Dellibovi-Ragheb T.A., Kerviel A., Pak E., Qiu Q., Fisher M.et al. . (2020) &#x3b2;-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell 183, 1520.e14&#x2013;1535.e14 10.1016/j.cell.2020.10.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.039</ArticleId><ArticleId IdType="pmc">PMC7590812</ArticleId><ArticleId IdType="pubmed">33157038</ArticleId></ArticleIdList></Reference><Reference><Citation>Inal J. (2020) COVID-19 comorbidities, associated procoagulant extracellular vesicles and venous thromboembolisms: a possible link with ethnicity? Br. J. Haematol. 190, e218&#x2013;e220 10.1111/bjh.17011</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17011</ArticleId><ArticleId IdType="pmc">PMC7361776</ArticleId><ArticleId IdType="pubmed">32645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Inal J. (2020) Complement-mediated extracellular vesicle release as a measure of endothelial dysfunction and prognostic marker for COVID-19 in peripheral blood - Letter to the Editor. Clin. Hemorheol. Microcirc. 75, 383&#x2013;386 10.3233/CH-200958</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/CH-200958</ArticleId><ArticleId IdType="pubmed">32925002</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalano M. and O'Driscoll L. (2020) Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J. Extracell. Vesicles 9, 1703244 10.1080/20013078.2019.1703244</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20013078.2019.1703244</ArticleId><ArticleId IdType="pmc">PMC6968539</ArticleId><ArticleId IdType="pubmed">32002167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosgodage U.S., Trindade R.P., Thompson P.R., Inal J.M. and Lange S. (2017) Chloramidine/Bisindolylmaleimide-I-mediated inhibition of exosome and microvesicle release and enhanced efficacy of cancer chemotherapy. Int. J. Mol. Sci. 18, 1007 10.3390/ijms18051007</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18051007</ArticleId><ArticleId IdType="pmc">PMC5454920</ArticleId><ArticleId IdType="pubmed">28486412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kongsomros S., Suksatu A., Kanjanasirirat P., Manopwisedjaroen S., Prasongtanakij S., Jearawuttanakul K.et al. . (2021) Anti-SARS-CoV-2 activity of extracellular vesicle inhibitors: screening, validation, and combination with remdesivir. Biomedicines 9, 1230 10.3390/biomedicines9091230</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9091230</ArticleId><ArticleId IdType="pmc">PMC8465755</ArticleId><ArticleId IdType="pubmed">34572416</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco S.J. and Huttenlocher A. (2005) Regulating cell migration: calpains make the cut. J. Cell Sci. 118, 3829&#x2013;3838 10.1242/jcs.02562</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.02562</ArticleId><ArticleId IdType="pubmed">16129881</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallick R.L., Kumari S., Singh N., Sonkar V.K. and Dash D. (2015) Prion protein fragment (106-126) induces prothrombotic state by raising platelet intracellular calcium and microparticle release. Cell Calcium 57, 300&#x2013;311 10.1016/j.ceca.2015.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2015.02.002</ArticleId><ArticleId IdType="pubmed">25749016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorfi S., Ansa-Addo E.A., Kholia S., Stratton D., Valley S., Lange S.et al. . (2015) Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo. Sci. Rep. 5, 13006 10.1038/srep13006</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep13006</ArticleId><ArticleId IdType="pmc">PMC4548233</ArticleId><ArticleId IdType="pubmed">26302712</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard D.L., Hubbard V.D., Burton J., Smee D.F., Morrey J.D., Otto M.J.et al. . (2004) Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antiviral Chem. Chemother. 15, 15&#x2013;22 10.1177/095632020401500102</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/095632020401500102</ArticleId><ArticleId IdType="pubmed">15074711</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Ikari J., Anazawa R., Tanaka N., Katsumata Y., Shimada A.et al. . (2020) PAD4 deficiency improves bleomycin-induced neutrophil extracellular traps and fibrosis in mouse lung. Am. J. Respir. Cell Mol. Biol. 63, 806&#x2013;818 10.1165/rcmb.2019-0433OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2019-0433OC</ArticleId><ArticleId IdType="pubmed">32915635</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandolfi L., Bozzini S., Frangipane V., Percivalle E., De Luigi A., Violatto M.B.et al. . (2021) Neutrophil extracellular traps induce the epithelial-mesenchymal transition: implications in post-COVID-19 fibrosis. Front. Imchengmunol. 12, 663303 10.3389/fimmu.2021.663303</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.663303</ArticleId><ArticleId IdType="pmc">PMC8236949</ArticleId><ArticleId IdType="pubmed">34194429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Yalavarthi S., Shi H., Gockman K., Zuo M., Madison J.A.et al. . (2020) Neutrophil extracellular traps in COVID-19. JCI Insight 5, e138999 10.1172/jci.insight.138999</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.138999</ArticleId><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Arisan E.D., Uysal-Onganer P. and Lange S. (2020) Putative roles for peptidylarginine deiminases in COVID-19. Int. J. Mol. Sci. 21, 4662 10.3390/ijms21134662</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21134662</ArticleId><ArticleId IdType="pmc">PMC7370447</ArticleId><ArticleId IdType="pubmed">32629995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Chen X. and Liu X. (2022) NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond. Front. Immunol. 13, 838011 10.3389/fimmu.2022.838011</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.838011</ArticleId><ArticleId IdType="pmc">PMC8924116</ArticleId><ArticleId IdType="pubmed">35309344</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;&#xdf;wein S., Lindemann A., Mahajan A., Mauer&#xf6;der C., Martini E., Patankar J.et al. . (2019) Citrullination licenses calpain to decondense nuclei in neutrophil extracellular trap formation. Front. Immunol. 10, 2481 10.3389/fimmu.2019.02481</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02481</ArticleId><ArticleId IdType="pmc">PMC6817590</ArticleId><ArticleId IdType="pubmed">31695698</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S.et al. . (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 180, 934&#x2013;943 10.1001/jamainternmed.2020.0994</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnolo P., Balestro E., Aliberti S., Cocconcelli E., Biondini D., Casa G.D.et al. . (2020) Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respiratory Med. 8, 750&#x2013;752 10.1016/S2213-2600(20)30222-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30222-8</ArticleId><ArticleId IdType="pmc">PMC7228737</ArticleId><ArticleId IdType="pubmed">32422177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemans R.L., Colgan S.P. and Downey G.P. (2009) Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am. J. Respir. Cell Mol. Biol. 40, 519&#x2013;535 10.1165/rcmb.2008-0348TR</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2008-0348TR</ArticleId><ArticleId IdType="pmc">PMC2677434</ArticleId><ArticleId IdType="pubmed">18978300</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Wells A.U. and Jenkins R.G. (2020) Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respiratory Med. 8, 807&#x2013;815 10.1016/S2213-2600(20)30225-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30225-3</ArticleId><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabata C., Tabata R. and Nakano T. (2010) The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice. Clin. Exp. Immunol. 162, 560&#x2013;567 10.1111/j.1365-2249.2010.04257.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2010.04257.x</ArticleId><ArticleId IdType="pmc">PMC3026560</ArticleId><ArticleId IdType="pubmed">20846163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynn T.A. (2011) Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208, 1339&#x2013;1350 10.1084/jem.20110551</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20110551</ArticleId><ArticleId IdType="pmc">PMC3136685</ArticleId><ArticleId IdType="pubmed">21727191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunz S., Niederberger E., Ehnert C., Coste O., Pfenninger A., Kruip J.et al. . (2004) The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia. Pain 110, 409&#x2013;418 10.1016/j.pain.2004.04.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2004.04.031</ArticleId><ArticleId IdType="pubmed">15275793</ArticleId></ArticleIdList></Reference><Reference><Citation>Muniappan L., Javidan A., Jiang W., Mohammadmoradi S., Moorleghen J.J., Katz W.S.et al. . (2017) Calpain inhibition attenuates adipose tissue inflammation and fibrosis in diet-induced obese mice. Sci. Rep. 7, 14398 10.1038/s41598-017-14719-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14719-9</ArticleId><ArticleId IdType="pmc">PMC5663911</ArticleId><ArticleId IdType="pubmed">29089532</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K. and Mehra M.R. (2020) COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J. Heart Lung Transpl. 39, 405&#x2013;407 10.1016/j.healun.2020.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2020.03.012</ArticleId><ArticleId IdType="pmc">PMC7118652</ArticleId><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttenlocher A., Palecek S.P., Lu Q., Zhang W., Mellgren R.L., Lauffenburger D.A.et al. . (1997) Regulation of cell migration by the calcium-dependent protease calpain. J. Biol. Chem. 272, 32719&#x2013;32722 10.1074/jbc.272.52.32719</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.52.32719</ArticleId><ArticleId IdType="pubmed">9407041</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenwaelder S.M., Yuan Y., Cooray P., Salem H.H. and Jackson S.P. (1997) Calpain cleavage of focal adhesion proteins regulates the cytoskeletal attachment of integrin alphaIIbbeta3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin clots. J. Biol. Chem. 272, 1694&#x2013;1702 10.1074/jbc.272.3.1694</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.3.1694</ArticleId><ArticleId IdType="pubmed">8999848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.H., Beckett J.D., Nagpal V., Seman-Senderos M.A., Gould R.A., Creamer T.J.et al. . (2019) Calpain 9 as a therapeutic target in TGF&#x3b2;-induced mesenchymal transition and fibrosis. Sci. Transl. Med. 11, eaau2814 10.1126/scitranslmed.aau2814</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau2814</ArticleId><ArticleId IdType="pmc">PMC7351287</ArticleId><ArticleId IdType="pubmed">31316008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou M., Zhang G., Zou J., Liu Y., Liu B., Hu X.et al. . (2020) Inhibition of the ERK1/2-ubiquitous calpains pathway attenuates experimental pulmonary fibrosis in vivo and in vitro. Exp. Cell. Res. 391, 111886 10.1016/j.yexcr.2020.111886</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2020.111886</ArticleId><ArticleId IdType="pubmed">32017927</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu B., Zhang G.Q., Zou J.F., Zou M.L. and Cheng Z.S. (2018) Calpain inhibition attenuates bleomycin-induced pulmonary fibrosis via switching the development of epithelial-mesenchymal transition. Naunyn-Schmiedeberg&#x2019;s Arch. Pharmacol. 391, 695&#x2013;704 10.1007/s00210-018-1499-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-018-1499-z</ArticleId><ArticleId IdType="pmc">PMC5994212</ArticleId><ArticleId IdType="pubmed">29666896</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Medina A., Lehmann M., Burgy O., Hermann S., Baarsma H.A., Wagner D.E.et al. . (2018) Increased extracellular vesicles mediate WNT5A signaling in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 198, 1527&#x2013;1538 10.1164/rccm.201708-1580OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201708-1580OC</ArticleId><ArticleId IdType="pubmed">30044642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C., Gudi K., Krause A., Sackrowitz R., Harvey B.G., Strulovici-Barel Y.et al. . (2011) Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am. J. Respir. Crit. Care Med. 184, 224&#x2013;232 10.1164/rccm.201012-2061OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201012-2061OC</ArticleId><ArticleId IdType="pmc">PMC3172886</ArticleId><ArticleId IdType="pubmed">21471087</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller A.M., Hermanns M.I., Skrzynski C., Nesslinger M., M&#xfc;ller K.M. and Kirkpatrick C.J. (2002) Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro. Exp. Mol. Pathol. 72, 221&#x2013;229 10.1006/exmp.2002.2424</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exmp.2002.2424</ArticleId><ArticleId IdType="pubmed">12009786</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie H., Gao Y.M., Zhang Y.C., Jia M.W., Peng F., Meng Q.H.et al. . (2020) Low let-7d exosomes from pulmonary vascular endothelial cells drive lung pericyte fibrosis through the TGF&#x3b2;RI/FoxM1/Smad/&#x3b2;-catenin pathway. J. Cell. Mol. Med. 24, 13913&#x2013;13926 10.1111/jcmm.15989</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15989</ArticleId><ArticleId IdType="pmc">PMC7753874</ArticleId><ArticleId IdType="pubmed">33179861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao M.Y., Zhang W.H., Ma W.T., Liu Q.H., Xing L.H. and Zhao G.F. (2019) microRNA-328 in exosomes derived from M2 macrophages exerts a promotive effect on the progression of pulmonary fibrosis via FAM13A in a rat model. Experiment. Mol. Med. 51, 1&#x2013;16 10.1038/s12276-019-0255-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-019-0255-x</ArticleId><ArticleId IdType="pmc">PMC6547742</ArticleId><ArticleId IdType="pubmed">31164635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji J., Su L. and Liu Z. (2016) Critical role of calpain in inflammation. Biomed. Rep. 5, 647&#x2013;652 10.3892/br.2016.785</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2016.785</ArticleId><ArticleId IdType="pmc">PMC5228304</ArticleId><ArticleId IdType="pubmed">28101338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetinkaya-Fisgin A., Luan X., Reed N., Jeong Y.E., Oh B.C. and Hoke A. (2020) Cisplatin induced neurotoxicity is mediated by Sarm1 and calpain activation. Sci. Rep. 10, 21889 10.1038/s41598-020-78896-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78896-w</ArticleId><ArticleId IdType="pmc">PMC7736304</ArticleId><ArticleId IdType="pubmed">33318563</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper A.K., Sophocleous R.A., Ross S.E., Evesson F.J., Saleh O., Bournazos A.et al. . (2020) Loss of calpains-1 and -2 prevents repair of plasma membrane scrape injuries, but not small pores, and induces a severe muscular dystrophy. Am. J. Physiol. Cell Physiol. 318, C1226&#x2013;C1237 10.1152/ajpcell.00408.2019</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00408.2019</ArticleId><ArticleId IdType="pubmed">32348180</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard I., Broux O., Allamand V., Fougerousse F., Chiannilkulchai N., Bourg N.et al. . (1995) Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81, 27&#x2013;40 10.1016/0092-8674(95)90368-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90368-2</ArticleId><ArticleId IdType="pubmed">7720071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Hersheson J., Lopez D., Hammer M., Liu Y., Lee K.H.et al. . (2016) Defects in the CAPN1 gene result in alterations in cerebellar development and cerebellar ataxia in mice and humans. Cell Rep. 16, 79&#x2013;91 10.1016/j.celrep.2016.05.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.05.044</ArticleId><ArticleId IdType="pmc">PMC4927383</ArticleId><ArticleId IdType="pubmed">27320912</ArticleId></ArticleIdList></Reference><Reference><Citation>Azam M., Andrabi S.S., Sahr K.E., Kamath L., Kuliopulos A. and Chishti A.H. (2001) Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol. Cell. Biol. 21, 2213&#x2013;2220 10.1128/MCB.21.6.2213-2220.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.21.6.2213-2220.2001</ArticleId><ArticleId IdType="pmc">PMC86855</ArticleId><ArticleId IdType="pubmed">11238954</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Li Y., Zhang H., Zhao R., Jing R., Xu Y.et al. . (2018) Zika virus propagation and release in human fetal astrocytes can be suppressed by neutral sphingomyelinase-2 inhibitor GW4869. Cell Discov. 4, 19 10.1038/s41421-018-0017-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-018-0017-2</ArticleId><ArticleId IdType="pmc">PMC5913238</ArticleId><ArticleId IdType="pubmed">29707233</ArticleId></ArticleIdList></Reference><Reference><Citation>Essandoh K., Yang L., Wang X., Huang W., Qin D., Hao J.et al. . (2015) Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. Biochim. Biophys. Acta 1852, 2362&#x2013;2371 10.1016/j.bbadis.2015.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.08.010</ArticleId><ArticleId IdType="pmc">PMC4581992</ArticleId><ArticleId IdType="pubmed">26300484</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaviya R., Laskin J.D. and Laskin D.L. (2017) Anti-TNF&#x3b1; therapy in inflammatory lung diseases. Pharmacol. Therapeut. 180, 90&#x2013;98 10.1016/j.pharmthera.2017.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2017.06.008</ArticleId><ArticleId IdType="pmc">PMC5693260</ArticleId><ArticleId IdType="pubmed">28642115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Xu B., Ma Z., Liu C., Deng Y., Liu W.et al. . (2017) Inhibition of calpains protects Mn-induced neurotransmitter release disorders in synaptosomes from mice: involvement of SNARE complex and synaptic vesicle fusion. Sci. Rep. 7, 3701 10.1038/s41598-017-04017-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04017-9</ArticleId><ArticleId IdType="pmc">PMC5473846</ArticleId><ArticleId IdType="pubmed">28623313</ArticleId></ArticleIdList></Reference><Reference><Citation>Apayd&#x131;n &#xc7;.B., &#xc7;&#x131;nar G. and Cihan-&#xdc;st&#xfc;nda&#x11f; G. (2021) Small-molecule antiviral agents in ongoing clinical trials for COVID-19. Curr. Drug Targets 22, 1986&#x2013;2005 10.2174/1389450122666210215112150</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450122666210215112150</ArticleId><ArticleId IdType="pubmed">33588727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanetta C., Nizzardo M., Simone C., Monguzzi E., Bresolin N., Comi G.P.et al. . (2014) Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clin. Ther. 36, 128&#x2013;140 10.1016/j.clinthera.2013.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2013.11.006</ArticleId><ArticleId IdType="pubmed">24360800</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson K.J., Yuan K., Plenderleith S.K., Watchon M. and Laird A.S. (2021) A novel calpain inhibitor compound has protective effects on a zebrafish model of spinocerebellar ataxia type 3. Cells 10, 2592 10.3390/cells10102592</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10102592</ArticleId><ArticleId IdType="pmc">PMC8533844</ArticleId><ArticleId IdType="pubmed">34685571</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazdyrev E., Rusina P., Panova M., Novikov F., Grishagin I. and Nebolsin V. (2021) Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals (Basel, Switzerland) 14, 807 10.3390/ph14080807</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14080807</ArticleId><ArticleId IdType="pmc">PMC8398080</ArticleId><ArticleId IdType="pubmed">34451904</ArticleId></ArticleIdList></Reference><Reference><Citation>Donkor I.O. (2015) An updated patent review of calpain inhibitors (2012 - 2014). Expert Opin. Ther. Pat. 25, 17&#x2013;31 10.1517/13543776.2014.982534</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543776.2014.982534</ArticleId><ArticleId IdType="pubmed">25399719</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>